Study Results

 
News Articles for Study Results top ^
IRVINGTON, N.Y., July 24, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA) , developer of the MelaFind ® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced new study results demonstrating the effectiveness of MelaFind predictive probability information when used by dermatology residents.
Sign-up for MELA Sciences Announces New Study Results Demonstrating Improved Diagnostic Accuracy for Resident Dermatologists When Utilizing MelaFind Predictive Probability Information investment picks
NEW YORK, July 24, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.
Sign-up for Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology investment picks
MIGDAL HA'EMEQ, Israel, July 7, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd.
Sign-up for Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage of INFAT(R) in Infants investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Kite Pharma Inc. surged in the extended session Monday after the biotech said most patients in a study responded well to its cancer drug candidate.
Sign-up for UPDATE: Kite Pharma shares fly high on study results investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Kite Pharma Inc. surged in the extended session Monday after the biotech said most patients in a study responded well to its cancer drug candidate.
Sign-up for Kite Pharma shares fly high on study results investment picks
Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR) , an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today presented positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). These results are being presented by George Bright, MD, Versartis Vice President of Clinical Development, during the clinical poster session, "Growth and GH: Diagnostic Issues and Treatment" from 1:00 – 3:00 p.m. CDT today at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL.
Sign-up for Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results investment picks
2014/7/24
Phase II Open Label Trial results for prescription drug candidate, CaPre® to be presented on July 26, 2014 at 12:30 p.m. LAVAL, Quebec, July 24, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19 th World Congress on Heart Disease.
Sign-up for Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Study Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Structured Finance  |  Next: Subject Companies